Anti-tumor efficacy of a potent and selective non-covalent KRAS[superscript G12D] inhibitor

Hallin, Jill; Bowcut, Vickie; Calinisan, Andrew; Briere, David M.; Hargis, Lauren; Engstrom, Lars D.; Laguer, Jade; Medwid, James; Vanderpool, Darin; Lifset, Ella; Trinh, David; Hoffman, Natalie; Wang, Xiaolun; Lawson, J.David; Gunn, Robin J.; Smith, Christopher R.; Thomas, Nicole C.; Martinson, Matthew; Bergstrom, Alex; Sullivan, Francis; Bouhana, Karyn; Winski, Shannon; He, Leo; Fernandez-Banet, Julio; Pavlicek, Adam; Haling, Jacob R.; Rahbaek, Lisa; Marx, Matthew A.; Olson, Peter; Christensen, James G.

doi:10.1038/s41591-022-02007-7

Title: Anti-tumor efficacy of a potent and selective non-covalent KRAS[superscript G12D] inhibitor

Journal Article · 01 October 2022 · Nat. Med.

DOI:https://doi.org/10.1038/s41591-022-02007-7· OSTI ID:1901103

Hallin, Jill; Bowcut, Vickie; Calinisan, Andrew; Briere, David M.; Hargis, Lauren; Engstrom, Lars D.; Laguer, Jade; Medwid, James; Vanderpool, Darin; Lifset, Ella; Trinh, David; Hoffman, Natalie; Wang, Xiaolun; Lawson, J.David; Gunn, Robin J.; Smith, Christopher R.; Thomas, Nicole C.; Martinson, Matthew; Bergstrom, Alex; Sullivan, Francis more »

Cite

Export

Save

Research Organization:: Argonne National Laboratory (ANL), Argonne, IL (United States). Advanced Photon Source (APS)

Sponsoring Organization:: DOE - Office Of Science; National Institutes of Health (NIH)

OSTI ID:: 1901103

Journal Information:: Nat. Med., Vol. 28

Country of Publication:: United States

Language:: ENGLISH

References (41)

Oncogenic Signaling Pathways in The Cancer Genome Atlas Sanchez-Vega, Francisco; Mina, Marco; Armenia, Joshua Cell, Vol. 173, Issue 2 https://doi.org/10.1016/j.cell.2018.03.035	journal	April 2018
RAS Proteins and Their Regulators in Human Disease Simanshu, Dhirendra K.; Nissley, Dwight V.; McCormick, Frank Cell, Vol. 170, Issue 1 https://doi.org/10.1016/j.cell.2017.06.009	journal	June 2017
The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity Canon, Jude; Rex, Karen; Saiki, Anne Y. Nature, Vol. 575, Issue 7781 https://doi.org/10.1038/s41586-019-1694-1	journal	October 2019
The KRAS ^G12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients Hallin, Jill; Engstrom, Lars D.; Hargis, Lauren Cancer Discovery, Vol. 10, Issue 1 https://doi.org/10.1158/2159-8290.CD-19-1167	journal	October 2019
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions Ostrem, Jonathan M.; Peters, Ulf; Sos, Martin L. Nature, Vol. 503, Issue 7477 https://doi.org/10.1038/nature12796	journal	November 2013
A model for RAS mutation patterns in cancers: finding the sweet spot Li, Siqi; Balmain, Allan; Counter, Christopher M. Nature Reviews Cancer, Vol. 18, Issue 12 https://doi.org/10.1038/s41568-018-0076-6	journal	November 2018
Biochemical and Structural Analysis of Common Cancer-Associated KRAS Mutations Hunter, J. C.; Manandhar, A.; Carrasco, M. A. Molecular Cancer Research, Vol. 13, Issue 9 https://doi.org/10.1158/1541-7786.MCR-15-0203	journal	June 2015
Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism Lito, P.; Solomon, M.; Li, L. -S. Science, Vol. 351, Issue 6273 https://doi.org/10.1126/science.aad6204	journal	January 2016
Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State Patricelli, M. P.; Janes, M. R.; Li, L. -S. Cancer Discovery, Vol. 6, Issue 3 https://doi.org/10.1158/2159-8290.CD-15-1105	journal	January 2016
Breaching the Cancer Fortress Olson, Peter; Hanahan, Douglas Science, Vol. 324, Issue 5933 https://doi.org/10.1126/science.1175940	journal	June 2009
Sotorasib for Lung Cancers with KRAS p.G12C Mutation Skoulidis, Ferdinandos; Li, Bob T.; Dy, Grace K. New England Journal of Medicine, Vol. 384, Issue 25 https://doi.org/10.1056/NEJMoa2103695	journal	June 2021
Methods for High-throughput Drug Combination Screening and Synergy Scoring He, Liye; Kulesskiy, Evgeny; Saarela, Jani Methods in Molecular Biology https://doi.org/10.1007/978-1-4939-7493-1_17	book	January 2018
Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer Cunningham, David; Humblet, Yves; Siena, Salvatore New England Journal of Medicine, Vol. 351, Issue 4 https://doi.org/10.1056/NEJMoa033025	journal	July 2004
EGF Receptor Signaling Is Essential for K-Ras Oncogene-Driven Pancreatic Ductal Adenocarcinoma Navas, Carolina; Hernández-Porras, Isabel; Schuhmacher, Alberto J. Cancer Cell, Vol. 22, Issue 3 https://doi.org/10.1016/j.ccr.2012.08.001	journal	September 2012
KRAS Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal Cancer Lièvre, Astrid; Bachet, Jean-Baptiste; Le Corre, Delphine Cancer Research, Vol. 66, Issue 8 https://doi.org/10.1158/0008-5472.CAN-06-0191	journal	April 2006
Comprehensive molecular characterization of human colon and rectal cancer Nature, Vol. 487, Issue 7407, p. 330-337 https://doi.org/10.1038/nature11252	journal	July 2012
Genomic analyses identify molecular subtypes of pancreatic cancer Bailey, Peter; Chang, David K. Nature, Vol. 531, Issue 7592 https://doi.org/10.1038/nature16965	journal	February 2016
Clinical Sequencing Defines the Genomic Landscape of Metastatic Colorectal Cancer Yaeger, Rona; Chatila, Walid K.; Lipsyc, Marla D. Cancer Cell, Vol. 33, Issue 1 https://doi.org/10.1016/j.ccell.2017.12.004	journal	January 2018
Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor Janes, Matthew R.; Zhang, Jingchuan; Li, Lian-Sheng Cell, Vol. 172, Issue 3 https://doi.org/10.1016/j.cell.2018.01.006	journal	January 2018
LBA6 KRYSTAL-1: Adagrasib (MRTX849) as monotherapy or combined with cetuximab (Cetux) in patients (Pts) with colorectal cancer (CRC) harboring a KRASG12C mutation Weiss, J.; Yaeger, R. D.; Johnson, M. L. Annals of Oncology, Vol. 32 https://doi.org/10.1016/j.annonc.2021.08.2093	journal	September 2021
Molecular genetics of pancreatic intraepithelial neoplasia Feldmann, Georg; Beaty, Robert; Hruban, Ralph H. Journal of Hepato-Biliary-Pancreatic Surgery, Vol. 14, Issue 3 https://doi.org/10.1007/s00534-006-1166-5	journal	May 2007
Presence of Somatic Mutations in Most Early-Stage Pancreatic Intraepithelial Neoplasia Kanda, Mitsuro; Matthaei, Hanno; Wu, Jian Gastroenterology, Vol. 142, Issue 4 https://doi.org/10.1053/j.gastro.2011.12.042	journal	April 2012
The Landscape of Actionable Genomic Alterations in Cell-Free Circulating Tumor DNA from 21,807 Advanced Cancer Patients Zill, Oliver A.; Banks, Kimberly C.; Fairclough, Stephen R. Clinical Cancer Research, Vol. 24, Issue 15 https://doi.org/10.1158/1078-0432.CCR-17-3837	journal	July 2018
Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden Chalmers, Zachary R.; Connelly, Caitlin F.; Fabrizio, David Genome Medicine, Vol. 9, Issue 1 https://doi.org/10.1186/s13073-017-0424-2	journal	April 2017
The consensus molecular subtypes of colorectal cancer Guinney, Justin; Dienstmann, Rodrigo; Wang, Xin Nature Medicine, Vol. 21, Issue 11 https://doi.org/10.1038/nm.3967	journal	October 2015
Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas Campbell, Joshua D.; Alexandrov, Anton; Kim, Jaegil Nature Genetics, Vol. 48, Issue 6 https://doi.org/10.1038/ng.3564	journal	May 2016
Insulin-Like Growth Factor Signaling as a Therapeutic Target in Pancreatic Cancer Rieder, Simon; W. Michalski, Christoph; Friess, Helmut Anti-Cancer Agents in Medicinal Chemistry, Vol. 11, Issue 5 https://doi.org/10.2174/187152011795677454	journal	June 2011
Crosstalk between Insulin/Insulin-like Growth Factor-1 Receptors and G Protein-Coupled Receptor Signaling Systems: A Novel Target for the Antidiabetic Drug Metformin in Pancreatic Cancer Rozengurt, Enrique; Sinnett-Smith, James; Kisfalvi, Krisztina Clinical Cancer Research, Vol. 16, Issue 9 https://doi.org/10.1158/1078-0432.CCR-09-2229	journal	April 2010
Insulin receptor functionally enhances multistage tumor progression and conveys intrinsic resistance to IGF-1R targeted therapy Ulanet, Danielle B.; Ludwig, Dale L.; Kahn, C. Ronald Proceedings of the National Academy of Sciences, Vol. 107, Issue 24 https://doi.org/10.1073/pnas.0914076107	journal	May 2010
K-ras Asp12 mutant neither interacts with Raf, nor signals through Erk and is less tumorigenic than K-ras Val12 Cespedes, M. V.; Sancho, F. J.; Guerrero, S. Carcinogenesis, Vol. 27, Issue 11 https://doi.org/10.1093/carcin/bgl063	journal	May 2006
Effect of KRAS Oncogene Substitutions on Protein Behavior: Implications for Signaling and Clinical Outcome Ihle, Nathan T.; Byers, Lauren A.; Kim, Edward S. JNCI: Journal of the National Cancer Institute, Vol. 104, Issue 3 https://doi.org/10.1093/jnci/djr523	journal	January 2012
XDS Kabsch, Wolfgang Acta Crystallographica Section D Biological Crystallography, Vol. 66, Issue 2 https://doi.org/10.1107/S0907444909047337	journal	January 2010
Overview of the CCP 4 suite and current developments Winn, Martyn D.; Ballard, Charles C.; Cowtan, Kevin D. Acta Crystallographica Section D Biological Crystallography, Vol. 67, Issue 4 https://doi.org/10.1107/S0907444910045749	journal	March 2011
Towards automated crystallographic structure refinement with phenix.refine Afonine, Pavel V.; Grosse-Kunstleve, Ralf W.; Echols, Nathaniel Acta Crystallographica Section D Biological Crystallography, Vol. 68, Issue 4 https://doi.org/10.1107/S0907444912001308	journal	March 2012
GRcalculator: an online tool for calculating and mining dose–response data Clark, Nicholas A.; Hafner, Marc; Kouril, Michal BMC Cancer, Vol. 17, Issue 1 https://doi.org/10.1186/s12885-017-3689-3	journal	October 2017
Xenome--a tool for classifying reads from xenograft samples Conway, T.; Wazny, J.; Bromage, A. Bioinformatics, Vol. 28, Issue 12 https://doi.org/10.1093/bioinformatics/bts236	journal	June 2012
Evaluation of GRCh38 and de novo haploid genome assemblies demonstrates the enduring quality of the reference assembly Schneider, Valerie A.; Graves-Lindsay, Tina; Howe, Kerstin Genome Research, Vol. 27, Issue 5 https://doi.org/10.1101/gr.213611.116	journal	April 2017
STAR: ultrafast universal RNA-seq aligner Dobin, Alexander; Davis, Carrie A.; Schlesinger, Felix Bioinformatics, Vol. 29, Issue 1 https://doi.org/10.1093/bioinformatics/bts635	journal	October 2012
limma powers differential expression analyses for RNA-sequencing and microarray studies Ritchie, Matthew E.; Phipson, Belinda; Wu, Di Nucleic Acids Research, Vol. 43, Issue 7 https://doi.org/10.1093/nar/gkv007	journal	January 2015
Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles Subramanian, A.; Tamayo, P.; Mootha, V. K. Proceedings of the National Academy of Sciences, Vol. 102, Issue 43, p. 15545-15550 https://doi.org/10.1073/pnas.0506580102	journal	September 2005
KRAS interaction with RAF1 RAS-binding domain and cysteine-rich domain provides insights into RAS-mediated RAF activation Tran, Timothy H.; Chan, Albert H.; Young, Lucy C. Nature Communications, Vol. 12, Issue 1 https://doi.org/10.1038/s41467-021-21422-x	journal	February 2021

Similar Records

Identification of MRTX1133, a Noncovalent, Potent, and Selective KRAS[superscript G12D] Inhibitor

Journal Article · 2022 · J. Med. Chem. · OSTI ID:1901103

Wang, Xiaolun; Allen, Shelley; Blake, James F.; +25 more

Identification of MRTX1133, a Noncovalent, Potent, and Selective KRAS[superscript G12D] Inhibitor

Journal Article · 2022 · J. Med. Chem. · OSTI ID:1901103

Wang, Xiaolun; Allen, Shelley; Blake, James F.; +25 more

Discovery of a Covalent Inhibitor of KRAS[superscript G12C] (AMG 510) for the Treatment of Solid Tumors

Journal Article · 2020 · J. Med. Chem. · OSTI ID:1901103

Lanman, Brian A.; Allen, Jennifer R.; Allen, John G.; +42 more

Title: Anti-tumor efficacy of a potent and selective non-covalent KRAS[superscript G12D] inhibitor

Citation Formats

References (41)

Similar Records

Related Subjects